Aquestive Therapeutics (AQST) logo

Aquestive Therapeutics (AQST) stock

Specialty medicines , market cap $449M

$3.91
+9.52%

Quality Score
1
Below Average
In its industry
#121of 270
Checks firing
3of 14
Trending down
From 52-week high
-41.9%
under its best in a year

AQST's Quality Score rose 4 points on Fri, Nov 13, to 1. More shares traded than usual (3 chart checks started).

Follow AQST's news. Pro members can get an alert when Aquestive Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when AQST files newsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextMar 16, 2027 · In 120 days“Anaphylm advances toward a March 16, 2027, PDUFA goal date following FDA acceptance of the NDA resubmission.”FDA decision date · SEC filing · Nov 5

Why AQST lags the market

Down 36% over five years while the S&P 500 rose 73%.

“The 41% decrease was primarily driven by the quarterly fluctuation of Suboxone product orders.”

Aquestive Therapeutics' Nov 3 release said

Sources: Price history, Nov 13, 2026; Company release, Nov 3, 2026

1 more reason, free with an account →5 more reasons why AQST lags the market, from its filings, with the other side, the company's words, the timeline, and its peers, for Pro members.

Key facts on AQST

Key facts on AQST
Holding it backA $79M loss wider than $69M a year earlier
Latest filing8-K, Nov 3 Reported its quarterly results
1 more reason behind AQST's 1, free with an account →6 more reasons behind AQST's 1, for Pro members.

AQST in the news

TodayNo company news in our sources; Biotech -0.6%, S&P 500 -0.4%.

Big story

Thu Oct 15: FDA

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

AQST closed −11.9% that day on 2.0x normal volume.

Reported by Yahoo Finance · covered by 3 outlets

Get an alert on AQST's next big story →

Outlet counts from the GDELT Project. The move is what AQST did that session, not a claim about why.

What's next

Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.

AQST catalysts

Coming up

After its last 4 reports it closed +1.5% on average, higher 1 of 4 times.

11 past catalysts since 2024, with sizes and sources, for Pro members.

What's next for AQST, and how long its cash lasts

Next step the company has named

Mar 16, 2027In 120 days“Anaphylm advances toward a March 16, 2027, PDUFA goal date following FDA acceptance of the NDA resubmission.”FDA decision date · SEC filing · Nov 5

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

For Pro members: 2 more milestones and 63 filings.

Cash runway

The company says its cash lasts into 2027 (8-K, May 13).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Apr 3, 2024)
  • At-the-market share sales program (424B2, filed Apr 24, 2024)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

Director Richard J. Daly bought 28,025 shares on Nov 10. 15 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Daniel Barber’s 29 filings and quotes.

Get an alert before AQST's FDA date

A free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

Why AQST scores 1

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

  • +3Chart checks 3 of 14 firing right now, one point each
  • −3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
  • News adds
  • Insider trades adds

No effect today: Run-up, Size, and Persistence.

What every line is worth, and the reason behind it, on AQST and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 5:25 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when AQST's Quality Score turns up

A free account. No card.Pro, 7 days free with a card.

How AQST ranks in Biotech

AQST is #121 of 270 by Quality Score.

How AQST ranks in Biotech
RankStockQuality Score
121Aquestive Therapeutics (AQST) logoAQSTAquestive Therapeutics1

More in Biotech

When does AQST report earnings, and what happens after?

Expected to report Wed Mar 3, after the close (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What AQST reported on Nov 3, 2026

The quarter

Sales of $7.6M, 41% less than a year ago; a loss of $0.13 a share, from $0.14.

“The 41% decrease was primarily driven by the quarterly fluctuation of Suboxone product orders.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Manufacture and Supply Revenuedown 42%$6.7M88%$11.9M86%$11.5M90%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)

4 more lines, for Pro members.

The outlook

The outlook the company gave, by period
MeasureFigure
Full year 2026
Total revenue$46.00 to $50.00

Figures as filed (SEC filing, Nov 3)

1 more outlook line, for Pro members.

The numbers

Market value
$449M
today
Sales
$48.8M
up 12.5% on the year
Free cash flow
-$40.7M
last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on AQST: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+14.5%-4.1%-2.1%
May 13Aug 11Nov 3
ReportedGapReaction5
days
Nov 3, 2026After close-5.7%-2.1%-9.3%
Aug 11, 2026After close-3.2%-4.1%-2.0%
May 13, 2026After close+15.0%+14.5%+1.0%

AQST closed higher after 1 of its last 4 reports.

All 4 reports, and AQST's Quality Score going into each

AQST sales and profit by year

Sales and profit by year

Sales grew in three of the last seven years, to $44.5M in 2025. It lost money in each of the eight years.

AQST has 3 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on AQST, and all 14 on every stock.Get in free →

AQST RSI on Nov 13: 47.8, below its 50-day and 200-day averages

Not scored

RSI 47.8, MACD above signal, below both averages. Not scored.

The deep dive on AQST

  • What it does and how it makes money5 findingsAn operating loss of $71.1M in fiscal 2025, on $44.5M of sales.Annual report, filed Mar 4, 2026"Under the terms of the Monetization Agreement, we sold all of our contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion’s apomorphine product, KYNMOBI." (10-K for fiscal 2025)SEC filing · Mar 4, 2026
  • Where it stands3 findingsFor Pro members3 findings on where AQST stands: its cash, debt, and share count, for Pro members
  • What changed in its filings7 findings"Our revenues to date have been earned from our manufactured products made to order for licensees … Libervant for ARS patients between two and five years of age which lost U.S. market access as a result of a court case challenging FDA's approval of Libervant in April 2025." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 3, 2026A new heading in its "Risk Factors" this year: "Changes in U.S. government policies, including those with respect to China, increased tariffs, and reductions in federal research funding, could adversely affect our business." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 4, 2026, against the one of Mar 5, 2025Indivor made up 73% of its revenue in fiscal 2025, up from 62% in fiscal 2024; Haisco made up 17%, up from 12% in fiscal 2024.SEC filing · Mar 4, 2026
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades AQST, for Pro members

12 more findings on AQST, each with its source, for Pro members.

AQST share count over time

Shares: 13.5% more than a year ago (to Sep 30).

Shares of AQST outstanding, as filed
Shares
outstanding
As
of
125.7MOct 30, 2026
125.5MAug 7, 2026
125.5MMay 11, 2026
122MMar 2, 2026
Offerings, shelves, and splits of AQST, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3)Jun 26, 2026
Priced a sale of sharesAug 14, 2025
Set up an at-the-market program for up to $100M of shares, about 22% of its market valueApr 24, 2024
Priced a sale of sharesApr 24, 2024

AQST insider trades

One insider bought $99K across 2 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyRichard J. Daly$95KDirectorat $3.55 on Nov 10, filed Nov 12

AQST's officers and directors

Officers and directors with a Form 4 in the last 12 months.

5 more officers and directors file at AQST.

See insider trades by person

Which ETFs hold AQST?

In ETFs: AQST is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

147 employeesWarren, NJaquestive.com

What Aquestive Therapeutics says it competes with

“We compete with pharmaceutical and biotechnology companies that develop and commercialize therapeutics for the treatment of a broad range of disease areas and indications.”

From its annual report, SEC filing · Mar 4, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on AQST and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn AQST's score around: 9 things
  • 14 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayNov 12Richard J. Daly bought AQST$95K at $3.54, filed Nov 12

Alerts are optional.

See AQST's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: AQST's Quality Score is 1 (Below Average), #121 of 270 in Biotech. Insiders bought $99K in the last 6 months (Form 4).

What does AQST's Quality Score say?

AQST scores 1 today, which Breakaway calls Below Average. It is #121 of 270 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 36% over five years while the S&P 500 rose 73%. Shares: 13.5% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is AQST's Quality Score?

AQST scores 1 today, which Breakaway calls Below Average (0 to 5). That is #121 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AQST's 1.

Are insiders buying AQST?

One insider bought $99K across 2 filings in the last 6 months. No open-⁠market sales on record. The newest is Richard J. Daly, Director, who bought $95K on Nov 10. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for Aquestive Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.